All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Amgen, Autolus, Jazz Pharmaceuticals, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View ALL content recommended for you
Studies have shown that pediatric-inspired asparaginase-based regimens improve outcomes in adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) / lymphoblastic leukemia (LBL) compared with conventional adult therapy, prompting updates to guideline recommendations from the National Comprehensive Cancer Network and European LeukemiaNet.1–6 However, AYAs often experience higher toxicity rates than pediatric populations and face unique psychosocial and access-related barriers, creating challenges in treatment implementation. These considerations have led to the development of expert recommendations to optimize treatment with asparaginase-based therapy within this patient population.1
The ALL Hub was pleased to speak with Wendy Stock, Luke Maese, and Ibrahim Aldoss to gain their expert insights on the rationale, key barriers, and recommendations associated with implementing pediatric-inspired regimens in AYAs with ALL.
.webp)
The ALL Hub was pleased to speak with Wendy Stock, the University of Chicago, US. We asked, What is the rationale for the use of pediatric-inspired asparaginase-based regimens in adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL)?
.webp)
Luke Maese discusses the key barriers associated with implementing asparaginase-based regimens in adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL).
.webp)
Ibrahim Aldoss, City of Hope, Duarte, US, discusses recommendations for addressing challenges in implementing asparaginase-based regimens in adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL).
This educational resource is independently supported by Jazz Pharmaceuticals. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Wendy Stock
Ibrahim T. Aldoss
Luke Maese.jpeg&w=3840&q=75)